October 5, 2022
Loading...
You are here:  Home  >  Health Care & Life Science  >  Current Article

MannKind rolls out a second cohort for inhalable insulin product

IN THIS ARTICLE

Westlake Village-based biotech company MannKind announced that it would begin enrolling a second cohort of pediatric patients in a safety study for its inhalable insulin product Afrezza. The initial cohort studied the safety and the passage of the drug through the body in patients 13 to 17 years old and found that the outcomes were…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.